These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7884404)

  • 21. Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neurons.
    Pepponi R; Ferrante A; Ferretti R; Martire A; Popoli P
    Eur J Pharmacol; 2009 Sep; 617(1-3):28-32. PubMed ID: 19619523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of intravenous anaesthetic agents on K(+)-evoked glutamate release from rat cerebrocortical slices. Involvement of voltage-sensitive Ca(2+) channels and GABA(A) receptors.
    Kitayama M; Hirota K; Kudo M; Kudo T; Ishihara H; Matsuki A
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):246-53. PubMed ID: 12172707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mouse cerebellar GABAB participation in the expression of acute ethanol-induced ataxia and in its modulation by the cerebellar adenosinergic A1 system.
    Dar MS
    Brain Res Bull; 1996; 41(1):53-9. PubMed ID: 8883916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposal of a guanine-based purinergic system in the mammalian central nervous system.
    Schmidt AP; Lara DR; Souza DO
    Pharmacol Ther; 2007 Dec; 116(3):401-16. PubMed ID: 17884172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of insulin release by adenosine A1 receptor agonists and antagonists in INS-1 cells: the possible contribution of 86Rb+ efflux and 45Ca2+ uptake.
    Töpfer M; Burbiel CE; Müller CE; Knittel J; Verspohl EJ
    Cell Biochem Funct; 2008 Dec; 26(8):833-43. PubMed ID: 18979526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors.
    Cunha RA
    Neurochem Int; 2001 Feb; 38(2):107-25. PubMed ID: 11137880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia.
    Parkinson FE; Rudolphi KA; Fredholm BB
    Gen Pharmacol; 1994 Oct; 25(6):1053-8. PubMed ID: 7875526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration.
    Gomes CV; Kaster MP; Tomé AR; Agostinho PM; Cunha RA
    Biochim Biophys Acta; 2011 May; 1808(5):1380-99. PubMed ID: 21145878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purinergic inhibition of neurotransmitter release in the central nervous system.
    Ribeiro JA
    Pharmacol Toxicol; 1995 Nov; 77(5):299-305. PubMed ID: 8778740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenosine, neurodegeneration and neuroprotection.
    Stone TW
    Neurol Res; 2005 Mar; 27(2):161-8. PubMed ID: 15829179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic and clinical aspects of adenosinergic neuromodulation.
    Marangos PJ; Boulenger JP
    Neurosci Biobehav Rev; 1985; 9(3):421-30. PubMed ID: 2866479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What can adenosine neuromodulation do for neuroprotection?
    Ribeiro JA
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):325-9. PubMed ID: 16101552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caffeine and Its Neuroprotective Role in Ischemic Events: A Mechanism Dependent on Adenosine Receptors.
    Pereira-Figueiredo D; Nascimento AA; Cunha-Rodrigues MC; Brito R; Calaza KC
    Cell Mol Neurobiol; 2022 Aug; 42(6):1693-1725. PubMed ID: 33730305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of adenosinergic system and its application for the treatment of epilepsy.
    Świąder MJ; Kotowski J; Łuszczki JJ
    Pharmacol Rep; 2014 Jun; 66(3):335-42. PubMed ID: 24905507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of taurine in the central nervous system.
    Wu JY; Prentice H
    J Biomed Sci; 2010 Aug; 17 Suppl 1(Suppl 1):S1. PubMed ID: 20804583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenosine: a prototherapeutic concept in neurodegeneration.
    von Lubitz DK; Carter MF; Beenhakker M; Lin RC; Jacobson KA
    Ann N Y Acad Sci; 1995 Sep; 765():163-78; discussion 196-7. PubMed ID: 7486604
    [No Abstract]   [Full Text] [Related]  

  • 37. Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.
    Bischofberger N; Jacobson KA; von Lubitz DK
    Ann N Y Acad Sci; 1997 Oct; 825():23-9. PubMed ID: 9369972
    [No Abstract]   [Full Text] [Related]  

  • 38. Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders.
    Abbracchio MP; Ceruti S; Brambilla R; Franceschi C; Malorni W; Jacobson KA; von Lubitz DK; Cattabeni F
    Ann N Y Acad Sci; 1997 Oct; 825():11-22. PubMed ID: 9369971
    [No Abstract]   [Full Text] [Related]  

  • 39. Neuromodulators and respiratory control in the infant.
    Lagercrantz H
    Clin Perinatol; 1987 Sep; 14(3):683-95. PubMed ID: 2889553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective role of adenosine in cerebral ischaemia.
    Rudolphi KA; Schubert P; Parkinson FE; Fredholm BB
    Trends Pharmacol Sci; 1992 Dec; 13(12):439-45. PubMed ID: 1293870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.